GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. - Wikidata - awgldk - TriplyDB

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

http://www.wikidata.org/entity/Q34591128

about

Vaccines for pancreatic cancer Cell death in the maintenance and abrogation of tolerance: the five Ws of dying cells The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis.Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Current immunotherapeutic approaches in pancreatic cancer.IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.The evolving biology and treatment of prostate cancer.SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.Immune cell recruitment and cell-based system for cancer therapy.What is recent in pancreatic cancer immunotherapy?Chitosan solution enhances the immunoadjuvant properties of GM-CSF.Rebuilding immunity in cancer patients.From cancer immunosurveillance to cancer immunotherapy.GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.Emerging cancer vaccines: the promise of genetic vectors.Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines.A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).Cancer vaccine by fusions of dendritic and cancer cells.Patented cancer vaccines: the promising leads.Unravelling the complexity of cancer-immune system interplay.Recent developments in prostate cancer biomarker research: therapeutic implications.Melanoma vaccines: developments over the past 10 years.Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study.Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines.An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors.Secretion of biologically active recombinant human granulocyte-macrophage colony-stimulating factor by transduced gastric cancer cells.Recombinant human granulocyte macrophage colony stimulating factor (hGM-CSF): Possibility of nanoparticle-mediated delivery in cancer immunotherapy.Selected anti-tumor vaccines merit a place in multimodal tumor therapies.Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy.Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

P2860

Q26825850-8EF5F3A9-9630-45B5-B798-1C7428312303 Q26999223-239EFAF3-0303-484C-B03E-4CE9712BA4C4 Q27024106-C7E57813-CD01-486B-B003-A51ADEED4E89 Q28732041-05DC6346-1D25-4CC9-ADB3-C3FD3045545B Q33703008-4B0334A2-925D-4E9E-9A1A-0E32EE846963 Q34914039-13F7C751-B79B-41E4-8625-7210E38772C5 Q35110264-23A67429-1238-4FFB-BEB9-9FB6B9F0B0B7 Q35212837-19CF30D3-C52C-4171-BE1C-91B36E36FB66 Q35886767-C78C4B26-58E7-4F75-814B-01424E38FDF0 Q35951473-92714934-798E-42B3-9329-20F1B159FF3F Q36491182-C89B927F-CC6B-4981-9EEC-45D5B6BBE678 Q36517706-A25DF94A-0F40-4372-9D0D-94654C290793 Q36665335-60EA5FA4-97CA-422D-8FB8-739B42A0A08D Q36868870-5FFE1696-B960-47FE-94AD-E5FC9E378DD9 Q36934947-08EE7E5F-9551-4BFE-8689-6229F3690977 Q36990588-88105C1B-E011-4E6B-AB3D-CBB7EF11A62E Q37012084-1A1330F2-74BD-4FB8-81A3-E430CC341CAB Q37137464-12637BCC-3BBB-4707-BCCC-413BB0C08393 Q37181792-D15C40BF-B080-462A-9057-E26C86D696FD Q37262109-45770C45-EDA1-49CE-8D38-279C1AC2B005 Q37334588-4C8F8411-3A2C-4ED0-BD4A-F909ADFAB955 Q37698219-B3EFA6CE-61F1-456A-92B6-1C51307A6674 Q37719552-70D31655-4C39-413B-9D13-81B7A784389E Q37765590-30FF5CBF-A7D6-4C73-BAC6-4DE657BB8CCB Q37827186-E56C67BE-9919-4C2D-969B-53906FBC92EC Q37892595-D2E79F2C-8FE5-46D8-BC48-89A4603FCC2D Q38125532-264642DD-63BC-4330-A6AE-1199B04412D0 Q38221692-5118759C-7012-4BB2-A8E5-66F2F2610F86 Q38585990-4562F504-BB70-4747-B46A-CC7F95FC5DF5 Q38721508-F1D5D887-F77A-4EE0-BA79-33946689ECC6 Q39633315-7059ADDF-5EBE-46CA-B94A-B7E44E0BD6D5 Q39924299-41DC5C29-7AA5-4CF7-B236-0A13DB13E5C6 Q39955401-FBECF9BF-AF0D-42C2-B080-D1AB9A790672 Q39986037-DCEAD1DF-1CA0-4468-B68F-ECDEE6A1D567 Q42290945-88F5F1DC-B383-464A-9002-06763C64735D Q42448191-EE954BA9-A20D-461F-87E8-8884B2AE237A Q42713856-58566AAC-5D01-4F41-BC91-6801A80B91A9 Q42983982-1E9E9A61-1ADF-4CBF-832A-AE3613234D65 Q47670865-302C28F7-60AA-46B6-89E9-9758BC14403A Q53491955-EAE1B4C3-771F-4627-851F-A3DE5D5F347E

P2860

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

http://www.wikidata.org/entity/Q34591128

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@en

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@nl

type

label

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@en

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@nl

prefLabel

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@en

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@nl

P1433

Q34591128-E084F5FB-A804-49D3-8B8C-E7B0E0C65A5E

P1476

Q34591128-6C824936-2058-47F7-A684-4341269B1F88

P2093

Q34591128-17C40955-7F77-4484-8841-F873C1855B49

Q34591128-406ADF82-9139-4E01-AD2C-C4C6198A7DAB

Q34591128-7F6A5F8A-6229-4565-AF2B-6E824EE1742B

P2860

Q34591128-02ED5D1A-198B-45D0-A464-22F8F22F6024

Q34591128-06B1C4B4-0AC4-44BD-84CA-BA30ED1C4B69

Q34591128-0E000E59-E8E5-4826-89DC-B9D1658134E2

Q34591128-0E86AE87-2816-4CD3-9493-7A42A8C2B373

Q34591128-0FC6D3B5-496A-4671-AB43-1E0C623E8330

Q34591128-145FE038-340B-4D55-A813-231DA52C6C44

Q34591128-15EE9242-FAEE-4036-9F4F-512D9C9E2925

Q34591128-22BA1ADB-BC5B-4B65-9B61-AAA4428AE0A0

Q34591128-2362C3E9-F7A1-4FAC-9C58-191D249A74C8

Q34591128-3D225CF3-6A29-473C-B8BD-748F225A4058

P304

Q34591128-D2C01ED9-DAD6-48C1-8340-A49F36E13AED

P31

Q34591128-1BB1E031-45DA-4AE5-9A9E-0B02DD76E6FC

P356

Q34591128-DC56A98D-BB6C-4EA7-954A-CF66FEB39823

P433

Q34591128-F32E7408-240C-4109-8FF0-416FD773C801

P478

Q34591128-04CF86AC-DF48-4D2A-9E1A-C7CD55B4C553

P577

Q34591128-6E566460-386E-42DF-A842-F65AE16F79F2

P698

Q34591128-A10D29FE-13DA-4D7E-9E20-5933AFB0C7E0

P921

Q34591128-08B9B476-021D-4768-9779-EDB802E294BF

P356

08830180600992498

P1433

International Reviews of Immunology

P1476

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

@en

P2093

Drew Pardoll

http://www.w3.org/2001/XMLSchema#string

Karin Jooss

http://www.w3.org/2001/XMLSchema#string

Kristen M Hege

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Dendritic cells and the control of immunity

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

Enhancement of antitumor immunity by CTLA-4 blockade

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.

P304

321-352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/08830180600992498

http://www.w3.org/2001/XMLSchema#string

P433

5-6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17169779

http://www.w3.org/2001/XMLSchema#string

P921